Oral Carbapenem Wins FDA Approval for cUTIs - Summary - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Oral Carbapenem Wins FDA Approval for cUTIs

Tebipenem pivoxil was noninferior to intravenous imipenem-cilastatin in hospitalized adults.

  • By

  • Kathryn Wighton

  • June 17, 2026

  • 2 min

Share

Objective:

To announce the FDA approval of tebipenem pivoxil for treating complicated urinary tract infections (cUTIs).

Approach:
    Key Findings:
    • Oral tebipenem pivoxil performed similarly to intravenous imipenem-cilastatin.
    • Common adverse reactions included diarrhea, headache, nausea, abdominal pain, increased liver enzymes, and Clostridioides difficile infection.
    Interpretation:

    The FDA has approved tebipenem pivoxil as the first oral carbapenem antibiotic in the US for cUTIs.

    Limitations:
    • Patients with allergies to tebipenem pivoxil or other beta-lactam antibacterials should not take the drug.
    • Not suitable for patients with primary or secondary carnitine deficiency or related metabolic errors.
    Conclusion:

    Tebipenem pivoxil is now available for adults with cUTIs who have limited or no oral treatment options.

    Sources:

Original Source(s)

Oral Carbapenem Wins FDA Approval for cUTIs

  • by Kathryn Wighton

  • June 17, 2026

Related Content

Extended Viral PCR: Does It Help?

Researchers evaluate whether extended viral PCR testing is associated with antibiotic use and length of stay in adult inpatients.

Dalbavancin Exposure Linked to Higher Success in Bacteremia

Higher day 22 concentrations were associated with improved outcomes, though findings remain exploratory

Fabricated Citations Are Reaching Medical Journals

A large audit of biomedical publications suggests fabricated references are increasingly appearing in peer-reviewed papers — often in ways that are difficult for reviewers and readers to detect.